Celgene thinks over the bid for Human Genome Sciences

Celgene

Celgene

According to a popular business magazine, Celgene Corp is considering the idea of bidding for Human Genome Sciences Inc. This is an alternative to the hostile offer that was made by GlaxoSmithKline Plc, a drug maker from Britain.

The bid of Glaxo for Human Genome:

Since it is Glaxo that reaps almost 50% of the profits coming from the drug Benlysta, conventional wisdom of the investors suggest that it was highly unlikely for Human Genome to find another bidder. The rights to the lupus drug named Benlysta are shared between Glaxo and Human Genome. Glaxo had made a bid for the shares of Human Genome at 13 dollars (or 8.39 pounds) for each share, amounting to 2.6 billion dollars. But Human Genome had till now refused the offer depicting it as very low. According to the prediction of the analysts of Wall Street as surveyed in the month of May by Reuters, the bid from Glaxo had to be increased to a minimum of about 15 dollars each share in order to succeed.

The other two bidders:

There are two companies apart from Glaxo that are in the process of discussion to make a bid for Human Genome according to reports from sources who are familiar with the situation. Among them Celgene is at a preferable position if it at all makes a bid. As per the source who talked on condition of anonymity stated that it would be more or less a merger of equals situation even though he did not quite identify the other bidder. It is on the 16th of July that the bid is supposed to end. On the one hand where representatives from Human Genome were not available for a comment, a spokesman from Celgene refused to make any comments on their activities related to acquisition.

About Celgene:

Celgene is one of the best companies related to biotechnology all over the world and is based at Summit in New Jersey. It is the manufacturer of drugs like Vidaza and Revlimid that are used for the treatment of blood cancer. Celgene is also in the process of developing a long line of drugs that can be used for treating autoimmune conditions like lupus and rheumatoid arthritis. Among them lupus is a dangerous disease in which the body of the patient is attacked by his own immune system. Celgene has since a long time been one of the most reliable growth stocks of the biotechnology market with a value of about 29 billion dollars.

Glaxo and Human Genome:

It was only last year the both Glaxo and Human Genome had won their approval for the drug Benlysta. This drug is the first source of treatment for the disease lupus in the last fifty years. But the launch of the drug proved quite disappointing as a result of which the share rates of Human Genome fell highly from a $25 to $6.51 in the month of December. Few months after that Glaxo made their bid for Human Genome that prompted them to coordinate an auction taking the help of Goldman Sachs and Credit Suisse.

 

Aubrey Chang
Aubrey Chang, Associate Editor Industry Leaders Magazine (www.industryleadersmagazine.com)

Recent Posts

UK’s Sanne agrees to consider Cinven bid

UK’s Sanne agrees to consider Cinven bid

Sanne, a UK fund administration business that provides alternative asset and corporate services, has agreed to hold talks with private equity firm Cinven over a potential £1.4bn t
6 hours ago
Global stocks rise as investors ignore inflations indicators

Global stocks rise as investors ignore inflations indicators

Global stocks rose to an all-time high, with investor showing confidence in a strong economic recovery from coronavirus and the vaccine effect, but the market is still a bit cautio
6 hours ago
UK watchdog whacks Amazon with probe for unfair data collection practices

UK watchdog whacks Amazon with probe for unfair data collection practices

The Competition and Markets Authority will focus on whether Amazon, Inc. favors merchants that use its delivery services.
3 days ago
Altice buys 12 percent stake in BT worth £2 billion

Altice buys 12 percent stake in BT worth £2 billion

Altice said it did not intend to make a bid for the British Telecoms company, though the takeover code also does not allow it to make an unsolicited buyout offer for six months wit
3 days ago
G7 countries agree on broad principles of minimum corporate tax deal

G7 countries agree on broad principles of minimum corporate tax deal

The world’s richest nations (G7) reached a landmark accord setting a global minimum corporate tax rate for multinationals. Would it be effective in tackling tax evasion and avoid
3 days ago
BC Partner goes the Continuation Fund way to strike a $7bn deal

BC Partner goes the Continuation Fund way to strike a $7bn deal

BC Partners, a UK private equity firm, has floated a “continuation fund” deal, one of Europe’s largest such deals, by transferring its 47 per cent stake in the academic publi
3 days ago